Supplementary material for Thomson DJ, et al. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. Acta Oncol 2015;54:88–98.

Supplementary Table I. Doses to planning target volumes and organs at risk.

Target volume	Parameter	Dose Required (Gy)	Mean Dose Achieved (Gy) (Dose Range, Gy)
PTV1 (62.5 Gy)	D99% > 90%Gy	> 56.3	58.7 (50.3–60.0)
	D95% > 95%Gy	> 59.4	60.3 (59.0–61.0)
	D50% = 100%Gy	= 62.5	62.8 (62.0–63.0)
	D2% < 110%Gy	< 68.8	64.4 (63.7–65.8)
PTV2 (55 Gy)	D99% > 90%Gy	> 49.5	52.9 (49.7–55.0)
	D95% > 95%Gy	> 52.3	53.7 (51.7–56.0)
PTV3 (50 Gy)	D99% > 90%Gy	> 45.0	46.8 (45.6–48.0)
	D95% > 95%Gy	> 47.5	48.3 (47.6–50.5)
High Risk OARs	Dose Constraint to 1cc of Volume (Gy)	Mean Dose Achieved (Gy) (Dose Range, Gy)	
Spinal cord PRV	< 45 Gy	41.3 (36.6–44.5)	
Brainstem PRV	< 54 Gy	40.3 (16.5–50.9)	
Low Risk OARs	Target Mean Dose Constraint (Gy)	Median Dose Achieved (Gy) (Dose Range, Gy)	
Ipsilateral Parotid Gland	As low as possible, < 24 Gy	43.0 (21.0–53.1)	
Contralateral Parotid Gland	< 24 Gy	25.6 (13.3–35.8)	
Larynx	< 40 Gy	35.6 (19.4–62.6)	

D, dose required to specified volume; Gy, gray; OARs, organs at risk; PTV, planning target volume; PRV, planning target volume.